Location Directory

Clinical trials in Miami, Florida

This page shows live ClinicalTrials.gov search results for Miami, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

12548

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Interventions: Paltusotine, Placebo; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 17
States / cities: Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more

Conditions: Coronary Artery Disease
Interventions: YMI024, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Fairhope, Alabama • Foley, Alabama • Los Angeles, California + 6 more

Conditions: Degenerative Disc Disease
Interventions: IDCT (rebonuputemcel), Sham (No Treatment); Biological · Other
Lead sponsor: DiscGenics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more

Conditions: Schizophrenia
Interventions: ML-007C-MA; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 45
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 39 more

Conditions: Pleural Malignant Mesothelioma
Interventions: Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more

Conditions: Systemic Lupus Erythematosus
Interventions: M5049 low dose, M5049 medium dose, M5049 high dose, Placebo; Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 8
States / cities: Torrance, California • Brandon, Florida • Miami, Florida + 5 more

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 36
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more

Conditions: Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma
Interventions: Epcoritamab; Biological
Lead sponsor: Izidore Lossos, MD; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Large B-cell Lymphoma, Relapse, DLBCL, DLBCL - Diffuse Large B Cell Lymphoma
Interventions: Epcoritamab, Loncastuximab Tesirine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Itepekimab SAR440340, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 1,127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 75
States / cities: Birmingham, Alabama • Jasper, Alabama • Chandler, Arizona + 56 more

Conditions: Sleep
Interventions: Increase sleep by 90 minutes, Decrease sleep by 90 minutes; Behavioral
Lead sponsor: Danisco; Industry
Eligibility: 20 Years to 40 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Boston, Massachusetts • Garden City, New York

Clinical trials in Miami, Florida

Filter and sort this location

Live official records

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Night Owl Sleep Study: The Effect of Sleep on Fecal Microbiota